WB
Vir
Transfected Only
200
Rabbit IgG
#P59594
1489668
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Specificity / Sensitivity
Species Reactivity:
Virus
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of SARS-CoV-1 spike protein.
Background
The cause of the SARS epidemic in 2003 was a novel pathogenic coronavirus, originally termed SARS-CoV (severe acute respiratory syndrome coronavirus) (1). Following the 2019 emergence of SARS-CoV-2 and the COVID-19 pandemic, SARS-CoV is now often referred to as SARS-CoV-1. SARS-CoV-1 is a member of the Coronaviridae family of viruses (2). The genome of SARS-CoV-1 is similar to other coronaviruses, and is comprised of four key structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N) (3). Coronavirus spike proteins are class I fusion proteins that harbor an ectodomain, a transmembrane domain, and an intracellular tail (4,5). The highly glycosylated ectodomain projects from the viral envelope surface and facilitates attachment and fusion with the host cell plasma membrane. The ectodomain can be further subdivided into host receptor-binding domain (RBD) (S1) and membrane-fusion (S2) subunits, which are produced upon proteolysis by host proteases at the S1/S2 junction, with possible secondary cleavage occurring at a downstream site (S2/S2’) (6). S1 and S2 subunits remain associated after cleavage and assemble into crown-like homotrimers (3,5). As with SARS-CoV-2, the SARS-CoV-1 spike protein utilizes the angiotensin-converting enzyme 2 (ACE2) protein as a receptor for cellular entry (7-9). Spike protein subunits represent a key antigenic feature of coronavirus virions, and therefore represent an important target of vaccines, novel therapeutic antibodies, and small-molecule inhibitors (10,11).
- Xu, R.H. et al. (2004) Emerg Infect Dis 10, 1030-7.
- Zhou, P. et al. (2020) Nature 579, 270-273.
- Tortorici, M.A. and Veesler, D. (2019) Adv Virus Res 105, 93-116.
- Li, F. et al. (2006) J Virol 80, 6794-800.
- Li, F. (2016) Annu Rev Virol 3, 237-261.
- Belouzard, S. et al. (2009) Proc Natl Acad Sci U S A 106, 5871-6.
- Shang, J. et al. (2020) Nature 581, 221-224.
- Wrapp, D. et al. (2020) Science 367, 1260-1263.
- Yan, R. et al. (2020) Science 367, 1444-1448.
- Yuan, Y. et al. (2017) Nat Commun 8, 15092.
- Amanat, F. and Krammer, F. (2020) Immunity 52, 583-589.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
